Planning is underway for the next stage of advanced preclinical studies and will include drug metabolism and pharmacokinetics as well as initiation of pharmaceutical drug development activities such ...
The MarketWatch News Department was not involved in the creation of this content. -- INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's -- Statistically significant ...
InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s Disease
InMed Pharmaceuticals (Nasdaq:INM) recently released preclinical data indicating its proprietary, small molecule compound, INM-901, targets multiple biological pathways associated with Alzheimer’s ...
Vancouver, British Columbia--(Newsfile Corp. - January 16, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization ...
Vancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results